The therapeutic vulnerability of PDA patients could be predicted by the profile of the KRAS/PI3K genome, suggesting that targeting PI3K in KRAS mutations may be a novel strategy for the treatment of CRC. Here, PIK3CD is linked to Patent ductus arteriosus.